Manufacturing Process
As a resulting of reaction of methansulfonylchloride reacted with aniline
methansulfonanilide was obtained. The methansulfonanilide reacted with
bromacetylbromide at the presence of AlCl3 and CS2 and 4-(bromacetyl)-
methansulfonanilide was prepeared.
Then to the 4-(bromacetyl)-methansulfonanilide isopropylamine was added to
give 4-(1-oxo-2-isopropylaminoethyl)methansulfonanilide.The 4-(1-oxo-2-isopropylaminoethyl)methansulfonanilide was reduced by
hydrogenesation in the presence of Pd-C catalyst and sodium borohydride. So
4-(1-hydroxy-2-isopropylaminoethyl)methansulfonanilide was obtained.
The 4-(1-hydroxy-2-isopropylaminoethyl)methansulfonanilide hydrochloride
may be prepared by treatment of base with hydrochloric acid.
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: NSAIDs antagonise hypotensive effect.
Anti-arrhythmics: increased risk of myocardial
depression and bradycardia; increased risk ofbradycardia, myocardial depression and AV block
with amiodarone; increased risk of ventricular
arrhythmias with amiodarone, dronedarone,
disopyramide or procainamide - avoid; increased
risk of myocardial depression and bradycardia with
flecainide.
Antibacterials: increased risk of ventricular
arrhythmias with moxifloxacin - avoid; increased
risk of ventricular arrhythmias with delamanid.
Antidepressants: enhanced hypotensive effect with
MAOIs; increased risk of ventricular arrhythmias
with tricyclics; increased risk of ventricular
arrhythmias with citalopram, escitalopram and
venlafaxine - avoid.
Antihistamines: increased risk of ventricular
arrhythmias with mizolastine - avoid.
Antihypertensives: enhanced hypotensive effect;
increased risk of withdrawal hypertension with
clonidine; increased risk of first dose hypotensive
effect with post-synaptic alpha-blockers such as
prazosin.
Antimalarials: increased risk of bradycardia with
mefloquine; avoid with artemether and lumefantrine
and piperaquine with artenimol - increased risk of
ventricular arrhythmias.
Antimuscarinics: increased risk of ventricular
arrhythmias with tolterodine.
Antipsychotics: enhanced hypotensive effect with
phenothiazines; increased risk of ventricular
arrhythmias with amisulpride, droperidol,
haloperidol, phenothiazines, pimozide, risperidone,
sulpiride or zuclopenthixol - avoid with droperidol
and zuclopenthixol.
Antivirals: increased risk of ventricular arrhythmias
with saquinavir or telaprevir - avoid.
Atomoxetine: increased risk of ventricular
arrhythmias.
Calcium-channel blockers: increased risk of
bradycardia and AV block with diltiazem;
hypotension and heart failure possible with
nifedipine and nisoldipine; asystole, severe
hypotension and heart failure with verapamil.
Cytotoxics: possible increased risk of bradycardia
with crizotinib; increased risk of ventricular
arrhythmias with vandetanib - avoid; increased risk
of ventricular arrhythmias with arsenic trioxide,
bosutinib, ceritinib, panobinostat and vandetanib.
Diuretics: enhanced hypotensive effect; increased risk
of ventricular arrhythmias due to hypokalaemia.
Fingolimod: possibly increased risk of bradycardia.
Ivabradine: increased risk of ventricular arrhythmias.
Moxisylyte: possible severe postural hypotension.
Ranolazine: avoid concomitant use.
Sympathomimetics: severe hypertension with
adrenaline and noradrenaline and possibly with
dobutamine.
